I like ALSK, any thoughts?
Buy and add on the dips.
Rather own ADRO
I'll just tag along worth the big boys.
I'm pretty sure earnings will be stellar.
Hold and add on the dips. 52 week highs by mid summer.
Sentiment: Strong Buy
GlaxoSmithKline (NYSE: GSK) will likely be kicking itself for returning its co-commercialization rights to the drug back to Amicus last year, and for selling its equity stake in Amicus this past October. Sanofi's Fabrazyme, an ultra-pricey twice-weekly injection that costs patients around $200,000 per year. Who will make a run at this company first.
I'm hoping for lower pps.